A Phase 2 interventional study of MTX in Rheumatoid Arthritis (RA), sponsored by Antares Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Antares Pharma Inc. (part of Halozyme Therapeutics) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 85th largest by enrollment, is one of 11 that started in 2012, is one of 10 in phase 2, and was the 62nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Antares Pharma Inc., one of the names counted as Halozyme Therapeutics. Under that name alone:
Antares Pharma Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Halozyme Therapeutics has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Relative Bioavailability Comparison study
A Phase 2, Open-Label, Randomized, 3-Way Crossover Study to Compare the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
Drug: MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
Drug: MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
Drug: MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
Drug: MTX
* Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group) * Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX) * Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
Also known as: Commercially available 2.5 mg MTX oral tablets, VIBEX MTX
Dose-Normalized AUC[0-Inf] for MTX
Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment
Time frame: 24 Hour period
Dose-Normalized AUC[0-24] for MTX
Dose-normalized area under the curve from time zero to 24 hours (AUC\[0-24\]/Dose) for each treatment
Time frame: 24 Hour period
Dose-Normalized Cmax for MTX
Dose-normalized maximum observed concentration (Cmax) for each treatment
Time frame: 24 Hour period
Subjects were screened and enrolled at 4 sites in the US. Approximately equal number of subjects on 10 mg, 15 mg, 20 mg and 25 mg doses were recruited. The dose group was determined by the Investigator based on subject's current therapeutic regimen of MTX and disease status. The subject's dose was the same for the entire study
| Milestone | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX |
|---|---|---|---|---|
| Started | 13 | 12 | 12 | 12 |
| Received treatment a | 12 | 12 | 12 | 11 |
| Received treatment b | 13 | 12 | 12 | 12 |
| Received treatment c | 12 | 12 | 12 | 11 |
| Completed | 12 | 12 | 12 | 11 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment
| ng*hr/mL/mg | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Dose-Normalized AUC[0-Inf] for MTX | 109.47 ± 39.19 | 140.84 ± 46.66 | 136.45 ± 46.675 |
Dose-normalized area under the curve from time zero to 24 hours (AUC\[0-24\]/Dose) for each treatment
| ng*hr/mL/mg | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Dose-Normalized AUC[0-24] for MTX | 107.64 ± 37.732 | 137.88 ± 44.513 | 133.78 ± 44.406 |
Dose-normalized maximum observed concentration (Cmax) for each treatment
| ng/mL/mg | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Dose-Normalized Cmax for MTX | 22.697 ± 7.496 | 21.935 ± 8.243 | 18.436 ± 5.321 |
Collected over The Safety Population was defined as all randomized subjects who received at least 1 dose of study drug. The Safety Population included 49 subjects.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10mg MTX | — | 0/13 (0%) | 2/13 (15.4%) |
| 15mg MTX | — | 1/12 (8.3%) | 0/12 (0%) |
| 20mg MTX | — | 0/12 (0%) | 1/12 (8.3%) |
| 25mg MTX | — | 1/12 (8.3%) | 0/12 (0%) |
| Event | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX |
|---|---|---|---|---|
| Sick Sinus Syndrome (15 mg Vibex MTX SC Thigh)Cardiac disorders | 0/13 | 1/12 | 0/12 | 0/12 |
| Myocardial Infarction (25 mg Vibex MTX SC Abdomen)Cardiac disorders | 0/13 | 0/12 | 0/12 | 1/12 |
| Event | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX |
|---|---|---|---|---|
| Nausea (20 mg MTX Oral)Gastrointestinal disorders | 0/13 | 0/12 | 1/12 | 0/12 |
| Fatigue (10 mg Vibex MTX SC Thigh)General disorders | 1/13 | 0/12 | 0/12 | 0/12 |
| Rheumatoid Arthritis (10 mg Vibex MTX SC Abdomen)Musculoskeletal and connective tissue disorders | 1/13 | 0/12 | 0/12 | 0/12 |
In total, 50 subjects were randomized, of which 49 were included in the safety population. Of 49, 47 completed the study and 2 discontinued from the study after first dose.
| Age, Continuous(years) | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX | Total |
|---|---|---|---|---|---|
| Mean | 62.9 ± 12.51 | 63.4 ± 7.49 | 60.0 ± 10.40 | 59.0 ± 11.53 | 61.4 ± 10.53 |
| Sex: Female, Male(Participants) | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX | Total |
|---|---|---|---|---|---|
| Female | 11 | 5 | 8 | 7 | 31 |
| Male | 2 | 7 | 4 | 5 | 18 |
| Race/Ethnicity, Customized(participants) | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX | Total |
|---|---|---|---|---|---|
| White | 12 | 11 | 10 | 11 | 44 |
| African American | 1 | 1 | 2 | 1 | 5 |
| Region of Enrollment(participants) | 10mg MTX | 15mg MTX | 20mg MTX | 25mg MTX | Total |
|---|---|---|---|---|---|
| United States | 13 | 12 | 12 | 12 | 49 |
The record gives a start of May 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate